A meta-analysis of efficacy and safety of genotype-guided versus standard of care treatment strategies in selecting antiplatelet therapy in patients with acute coronary syndrome
- 1 April 2021
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 97 (5), 788-794
- https://doi.org/10.1002/ccd.28860
Abstract
Background Previous studies have shown similar rates of major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS) patients, treated with P2Y(12) inhibitors based on genotype guidance compared to standard treatment. However, given lower than expected event rates, these studies were underpowered to assess hard outcomes. We sought to systematically analyze this evidence using pooled data from multiple studies. Methods Electronic databases were searched for studies of ACS patients that underwent genotype-guided treatment (GGT) with P2Y(12) inhibitors versus standard of care treatment (SCT). Studies with a minimum follow-up of 12 months were included. Rate of MACE (defined as a composite of cardiovascular [CV] mortality, nonfatal myocardial infarction [MI], and nonfatal stroke) was the primary outcome. Secondary outcomes were individual components of MI, CV mortality, ischemic stroke, stent thrombosis, and major bleeding. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated and combined using random effects model meta-analysis. Results A total of 4,095 patients (2007 in the GGT and 2088 in the SCT group were analyzed from three studies). Significantly lower odds of MACE (6.0 vs. 9.2%; OR: 0.63, 95% CI: 0.50-0.80, p < .001, I-2 = 0%) and MI (3.3 vs. 5.45%; OR: 0.63; CI 0.41-0.96; p = .03; I-2 = 46%) were noted in the GGT group compared to SCT. No significant difference was noted with respect to CV and other secondary outcomes. Conclusion In patients with ACS, genotype-guided initiation of P2Y(12) inhibitors was associated with lower odds of MACE and similar bleeding risk in comparison to SCT.This publication has 29 references indexed in Scilit:
- Thrombotic Complications Associated With Early and Late Nonadherence to Dual Antiplatelet TherapyJACC: Cardiovascular Interventions, 2015
- Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data RegistryJournal of the American Heart Association, 2014
- Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary InterventionCirculation: Cardiovascular Quality and Outcomes, 2013
- Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trialInternational Journal of Cardiology, 2013
- Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary StentingThe New England Journal of Medicine, 2012
- Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trialThe Lancet, 2012
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine DiphosphateJournal of the American College of Cardiology, 2010
- Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal StentsCirculation, 2009
- Early Stent ThrombosisCirculation, 2009